[1] McLaughlin PJ, Sassani JW, Zagon IS. Naltrexone as a novel therapeutic for diabetic corneal complications[J]. J Cell Immunol, 2020,2(2):42-46. DOI: 10.33696/immunology. 1.018.
[2] Solanki A, Bhatt LK, Johnston TP, et al. Targeting matrix metalloproteinases for diabetic retinopathy: the way ahead?[J]. Curr Protein Pept Sci, 2019,20(4):324-333. DOI: 10.2174/1389203719666180914093109.
[3] Opdenakker G, Abu El-Asrar A. Metalloproteinases mediate diabetes-induced retinal neuropathy and vasculopathy[J]. Cell Mol Life Sci, 2019,76(16):3157-3166. DOI: 10.1007/s00018-019-03177-3.
[4] Kimura T, Tanaka N, Fujimori N, et al. Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD[J]. Liver Int, 2021,41(3):505-514. DOI: 10.1111/liv.14776.
[5] 中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)[J].中华眼科杂志,2014,50(11):851-865.DOI:10.3760/cma.j.issn.0412-4081.2014.11.014.
[6] Roy S, Kern TS, Song B, et al. Mechanistic insights into pathological changes in the diabetic retina: implications for targeting diabetic retinopathy[J]. Am J Pathol, 2017,187(1):9-19. DOI: 10.1016/j.ajpath.2016.08.022.
[7] Lechner J, O'Leary OE, Stitt AW. The pathology associated with diabetic retinopathy[J]. Vision Res, 2017,139:7-14. DOI: 10.1016/j.visres.2017.04.003.
[8] Spencer BG, Estevez JJ, Liu E, et al. Pericytes, inflammation, and diabetic retinopathy[J]. Inflammopharmacology, 2020,28(3):697-709. DOI: 10.1007/s10787-019-00647-9.
[9] Nakao T, Morita H. Thrombospondin-2[J]. Int Heart J, 2019,60(2):235-237. DOI: 10.1536/ihj.19-042.
[10] Pan W, Song XY, Hu QB, et al. TSP2 acts as a suppresser of cell invasion, migration and angiogenesis in medulloblastoma by inhibiting the Notch signaling pathway[J]. Brain Res, 2019,1718:223-230. DOI: 10.1016/j.brainres.2019.05.004.
[11] Saini DC, Kochar A, Poonia R. Clinical correlation of diabetic retinopathy with nephropathy and neuropathy[J]. Indian J Ophthalmol, 2021,69(11):3364-3368. DOI: 10.4103/ijo.IJO_1237_21.
[12] Wu YB, Wang CG, Xu LX, et al. Analysis of risk factors for progressive fibrovascular proliferation in proliferative diabetic retinopathy[J]. Int Ophthalmol, 2020,40(10):2495-2502. DOI: 10.1007/s10792-020-01428-y.
[13] Zhang G, Chen H, Chen W, et al. Prevalence and risk factors for diabetic retinopathy in China: a multi-hospital-based cross-sectional study[J]. Br J Ophthalmol, 2017,101(12):1591-1595. DOI: 10.1136/bjophthalmol-2017-310316.
|